Business Context and Reporting Period
This Form 8-K was filed by pSivida Corp. on March 22, 2013. The report addresses Item 8.01 (Other Events) regarding updates from Alimera Sciences, Inc., a partner company, concerning the drug ILUVIEN for diabetic macular edema.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The material change reported is the issuance of a press release by pSivida Corp. detailing updates from Alimera Sciences, Inc. regarding:
- The expected timing for the resubmission of a New Drug Application (NDA) for ILUVIEN to the U.S. Food and Drug Administration (FDA).
- The expected timing for the commencement of ILUVIEN shipments in Germany.
- The submission of a patient access scheme for ILUVIEN.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the aforementioned regulatory and commercial milestones. The filing does not contain specific forward-looking guidance, risk factors, contingencies, or unusual items beyond the referenced press release (Exhibit 99.1).
Investor Verification Checklist
- Verify the specific dates for the FDA NDA resubmission and German shipment commencement in the attached press release (Exhibit 99.1).
- Confirm the details of the patient access scheme submitted for ILUVIEN.
- Review the relationship and financial impact of Alimera Sciences, Inc.'s progress on pSivida Corp.'s future revenue streams.